DUSP9 and alveolar soft part sarcoma: To further analyze the immunotherapy response of DUSP9 and TNFSF14, we collected primary site tumors and metastatic tissue from two locally advanced alveolar soft part sarcoma (ASPS) patients who received immunotherapy combined with anti-angiogenic drugs, matched with clinical features in our center.